Immune cell modulators are a novel therapeutic class with the potential to deliver differentiated outcomes in autoimmune and inflammatory diseases including dermatology, gastroenterology, and rheumatology
-
Checkpoint agonists “hit the brakes” to restore immune balance and deliver differentiated outcomes
-
ANB032 (BTLA agonist) modulates activated immune cells:
– Non-depleting
- Reduce T cell proliferation and reduce cytokine secretion (Th1, Th2, Th17, Th22)
- Modulate dendritic cells and induce Tregs
- Agonize B cells
Rosnilimab (PD-1 agonist) specifically targets activated T cells:
– Depleting PD-1high T cells
- Reduce T cell migration, proliferation & cytokine secretion
- Reduce plasma cell generation & autoantibody levels
-
Membrane-proximal binding epitope and optimized Fc receptor binding affinity enables tight immune synapse and best-in-class potency
- Oral Presentation
September, 2024 — European Society of Dermatological Research (ESDR) Annual Meeting
ANB032, an Investigational BTLA Agonist Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and Prolonged Survival in a Mouse Model of Graph versus Host Disease (GvHD)
Hare et al., 2024
- Oral Presentation
September, 2024 — European Society of Dermatological Research (ESDR) Annual Meeting
ANB032, an Investigational BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis (AD) Pathophysiology
Soroosh et al., 2024
- Poster Presentation
September, 2024 — European Society of Dermatological Research (ESDR) Annual Meeting
ANB032, an Investigational BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology
Soroosh et al., 2024
- Poster Presentation
September, 2024 — European Society of Dermatological Research (ESDR) Annual Meeting
ANB032, an Investigational BTLA Agonist Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and Prolonged Survival in a Mouse Model of Graph versus Host Disease
Hare et al., 2024
- Poster Presentation
June, 2024 — Federation of Clinical Immunology Societies (FOCiS) Annual Meeting
ANB032, a BTLA (B and T Cell Lymphocyte Attenuator) Checkpoint Receptor Agonist, Modulates Dendritic Cell Maturation and Function
Soroosh et al., 2024
- Poster Presentation
May, 2024 — Society of Investigative Dermatology (SID) Annual Meeting
ANB032, a BTLA Checkpoint Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion and Prevented Graft versus Host Disease (GvHD) in a Mouse Model
Hare et al., 2024
- Oral Presentation
May, 2024 — American Association of Immunology (AAI) Annual Meeting
ANB032, a BTLA Checkpoint Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion and Prevented Graft versus Host Disease (GvHD) in a Mouse Model
Hare et al., 2024
- Poster Presentation
May, 2024 — American Association of Immunology (AAI) Annual Meeting
ANB032, a BTLA Checkpoint Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion and Prevented Graft versus Host Disease (GvHD) in a Mouse Model
Hare et al., 2024
- Poster Presentation
March, 2024 — American Academy of Dermatology (AAD) Annual Meeting
ANB032, an Investigational B and T Cell Lymphocyte Attenuator (BTLA) Checkpoint Receptor Agonist, Modulates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology
Muench et al., 2024
- Poster Presentation
February, 2024 - American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells
Luu et al., 2024
- Poster Presentation
November, 2023 — 5th Inflammatory Skin Disease Summit (ISDS)
A Phase 2b, Randomized, Double Blind, Placebo Controlled, Global Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Moderate to Severe Atopic Dermatitis
Ehst et al., 2023
- Poster Presentation
November, 2023 — 5th Inflammatory Skin Disease Summit (ISDS)
ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study
Luu et al., 2023
- Oral Presentation
October, 2023 — European Academy of Dermatology and Venerology (EADV) Congress
ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study
Luu et al., 2023
- Poster Presentation
October, 2023 — European Academy of Dermatology and Venerology (EADV) Congress
A Phase 2b, Randomized, Double Blind, Placebo Controlled, Multicenter, Global Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
Silverberg et al., 2023
- Oral Presentation
June, 2024 — Federation of Clinical Immunology Societies (FOCiS) Annual Meeting
Rosnilimab, a PD-1 Agonist Antibody that Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling
Parmley et al., 2024
- Poster Presentation
June, 2024 — Federation of Clinical Immunology Societies (FOCiS) Annual Meeting
Rosnilimab, a PD-1 Agonist Antibody that Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling
Parmley et al., 2024
- Oral Presentation
May, 2024 — Digestive Disease Week (DDW) Annual Meeting
Optimizing PD-1 Agonist Signaling With Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Parmley et al., 2024
- Poster Presentation
May, 2024 — Digestive Disease Week (DDW) Annual Meeting
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1+ Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial
Luu et al., 2024
- Oral Presentation
February, 2024 — European Crohn’s and Colitis Organisation (ECCO) Congress
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduces T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1high Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial
Luu et al., 2024
- Poster Presentation
February, 2024 — European Crohn’s and Colitis Organisation (ECCO) Congress
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Parmley et al., 2024
- Poster Presentation
November, 2023 — American College of Rheumatology (ACR) Convergence
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial
Luu et al., 2023
- Poster Presentation
November, 2023 — American College of Rheumatology (ACR) Convergence
Optimizing PD-1 Agonist Signaling with Membrane-Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Parmley et al., 2023
- Poster Presentation
November, 2022 — Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Demonstrated Modulation of Peripheral T Cell Activity and Reduction of Circulating PD-1 high Expressing CD4 and CD8 T Cells in a Phase 1 Healthy Volunteer Clinical Trial
Dahl et al., 2022
- Journal Publication
December, 2023 — Nature
PD‑1‑Positive Cells Contribute to the Diagnosis of Inflammatory Bowel Disease and Can Aid in Predicting Response to Vedolizumab
Kim et al., 2023
- Journal Publication
January, 2023 — Science Immunology
Anti–PD-1 Antibodies Recognizing the Membrane Proximal Region are PD-1 Agonists that can Downregulate Inflammatory Diseases
Suzuki et al., 2023
- Journal Publication
June, 2020 — International Immunology
PD-1 and PD-1 Ligands: From Discovery to Clinical Application
Okazaki et al., 2020
- Journal Publication
February, 2018 — PLOS ONE
Immune Checkpoint Inhibitor PD-1 Pathway is Down-Regulated in Synovium at Various Stages of Rheumatoid Arthritis Disease Progression
Guo et al., 2018
- Journal Publication
June, 2017 — Molecular Medicine Reports
Elevated Expression of PD‑1 on T Cells Correlates with Disease Activity in Rheumatoid Arthritis
Luu et al., 2018
- Poster Presentation
June, 2023 — Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
Discovery of a Novel High Affinity Anti-Human CD122 Antagonist Monoclonal Antibody (ANB033) that Abrogates IL-2 and IL-15 Signaling for the Treatment of T Cell-Mediated Inflammatory and Autoimmune Diseases
Hare et al., 2023
- Oral Presentation
October, 2021 — European Academy of Dermatology and Venereology (EADV) Annual Congress
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial
Gudjonsson et al., 2021
- Poster Presentation
May, 2018 — European Academy of Allergy and Clinical Immunology (EAACI) Congress
A Phase 1 Study of ANB019, an Anti-Interleukin-36-Receptor (IL-36R) Monoclonal Antibody, in Healthy Volunteers
Khanskaya et al., 2018
- Journal Publication
April, 2023 — British Journal of Dermatology
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial
Warren et al., 2023
- Journal Publication
November, 2013 — Journal of Investigative Dermatology
The Majority of Generalized Pustular Psoriasis Without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist
Sugiura et al., 2013
- Journal Publication
August, 2012 — Current Opinion in Pharmacology
IL-36 in Psoriasis
Towne et al., 2012
- Journal Publication
2012 — Expert Review of Dermatology
IL-36: a Potential Psoriasis Target?
Raison et al., 2012
- Journal Publication
September, 2011 — The American Journal of Human Genetics
Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis
Onoufriadis et al., 2011
- Journal Publication
August, 2011 — The New England Journal of Medicine
Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis
Marrakchi et al., 2011
- Journal Publication
February, 2011 — The Journal of Immunology
IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide Expression
Johnston et al., 2011
- Journal Publication
October, 2007 — Journal of Experimental Medicine
Opposing Activities of Two Novel Members of the IL-1 Ligand Family Regulate Skin Inflammation
Blumberg et al., 2007
- Poster Presentation
2016 — EORTC-NCI-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics
Identification and Characterization of TSR-042, a Novel Anti-PD-1 Therapeutic Antibody
Laken et al., 2016
- Poster Presentation
2016 — EORTC-NCI-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics
Discovery of TSR-022, a Novel, Potent Anti-TIM-3 Therapeutic Antibody
Laken et al., 2016
- Poster Presentation
2015 — American Association for Cancer Research Annual Meeting
Targeting PD-1, TIM-3 and LAG-3 in Combination for Improved Immunotherapy Combinations
Kehry et al., 2015
- Poster Presentation
2015 — Keystone Symposium on Antibodies as Drugs
Generation of Anti-LAG-3 Monoclonal Antibodies for use in Immunotherapy Combinations
Jun et al., 2015
- Poster Presentation
2014 — American Association for Cancer Research Special Conference on Tumor Immunology and Immunotherapy
Identification and Characterization of a Potent Anti-Human Tim-3 Antagonist
Correia et al., 2014
- Poster Presentation
2014 — American Association for Cancer Research Annual Meeting
Generation of Antagonistic Anti-TIM-3 and LAG-3 Monoclonal Antibodies for Potential Novel Immunotherapy Combinations
Jun et al., 2014
- Journal Publication
July, 2021 — mAbs
Preclinical Characterization of Dostarlimab, a Therapeutic Anti-PD-1 Antibody with Potent Activity to Enhance Immune Function in in Vitro Cellular Assays and in Vivo Animal Models
Kumar et al., 2021